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Abstract
Background: Inflammation is considered to be of primary pathogenic importance in COPD but
the evidence on which current understanding is based does not distinguish between cause and
effect, and no single mechanism can account for the complex pathology. We performed a
prospective longitudinal study of subjects with COPD that related markers of sputum inflammation
at baseline to subsequent disease progression.
Methods: A cohort of 56 patients with chronic bronchitis was characterized in the stable state at
baseline and after an interval of four years, using physiological measures and CT densitometry.
Sputum markers of airway inflammation were quantified at baseline from spontaneously produced
sputum in a sub-group (n = 38), and inflammation severity was related to subsequent disease
progression.
Results: Physiological and CT measures indicated disease progression in the whole group. In the
sub-group, sputum myeloperoxidase correlated with decline in FEV1 (rs = -0.344, p = 0.019, n =
37). LTB4 and albumin leakage correlated with TLCO decline (rs = -0.310, p = 0.033, rs = -0.401,
p = 0.008, respectively, n = 35) and IL-8 correlated with progression of lung densitometric indices
(rs = -0.464, p = 0.005, n = 38).
Conclusion: The data support a principal causative role for neutrophilic inflammation in the
pathogenesis of COPD and suggest that the measurement of sputum inflammatory markers may
have a predictive role in clinical practice.
Background
Chronic obstructive pulmonary disease (COPD) is a
slowly progressive condition characterised by airflow
obstruction that is 'not fully reversible' [1]. The main aeti-
ological factor is cigarette smoking and it is generally
accepted that the pathogenic mechanism is the develop-
ment of an abnormal inflammatory response to inhaled
particles and gases in the lung. Exposure to tobacco smoke
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appears to be universally associated with lung inflamma-
tion, but only a proportion of smokers develop COPD.
Nevertheless, an enhanced inflammatory response has
been demonstrated in the lungs of susceptible individuals
that is more marked with continuing exposure to tobacco
smoke [2] and the level of inflammation has been shown
to relate to disease severity [3-6]. In addition, sputum neu-
trophilia has been related to FEV1 decline over the preced-
ing 15 years [7]. Consequently, lung inflammation is
likely to play a primary pathogenic role and offers a com-
mon unifying theme to the varied clinical phenotype seen
in COPD [8]. However, the design of these studies does
not allow cause to be distinguished from effect and, con-
sequently, prospective studies that relate inflammation to
disease progression are required to validate the inflamma-
tory hypothesis of COPD causation. In addition, a pro-
spective study design may also assist in resolving the lack
of consensus over the relative importance of different
inflammatory mechanisms.
Disease progression in longitudinal studies of COPD has
traditionally been assessed using FEV1 but this is a non-
specific measure of airflow obstruction that does not iden-
tify the relative contribution of the component parts of
this heterogeneous syndrome. Co-existing impairment of
gas exchange implies the presence of emphysema but this
too is a non-specific measure and, in addition, emphy-
sema is defined in morphological rather than physiologi-
cal terms [9]. Consequently, the development of CT
densitometry as a valid in vivo measure of emphysema
[10,11] offers an opportunity to characterise individual
phenotype in more detail and to clarify the contribution
of emphysematous destruction to the decline in FEV1. In
studies of subjects with alpha 1-antitrypsin deficiency
(AATD), it has been shown to be a more sensitive measure
of disease progression than either physiology or health
status indices [12] and to relate to the decline in the gold
standard method, namely FEV1 [13]. However, the clinical
phenotype in usual COPD is generally considered to be
more heterogeneous than in AATD and the role of CT den-
sitometry in longitudinal studies is less well established.
The current study was performed to characterise, in detail,
disease progression over a 4-year interval in a cohort of
subjects with COPD and chronic bronchitis. Markers of
neutrophilic inflammation in sputum were measured in a
sub-group of individuals at baseline and were related to
subsequent disease progression, assessed using traditional
physiological measurements and contemporary CT densi-
tometry.
Methods
Subjects
Subjects aged 40–80 years with smoking related chronic
bronchitis [14] were recruited from two sources; firstly,
from a cohort of subjects enrolled in a study of exacerba-
tions of COPD (n = 46) [15] and secondly, from subjects
attending a specialist out-patient COPD clinic (n = 10).
Serum alpha 1-antitrypsin levels were assayed using
immunoassay.
Study design
Assessment at baseline included lung function testing,
computed tomography with lung densitometry, character-
isation of sputum inflammation and microbiology.
Patients were invited to attend four years after their initial
visit in order to assess disease progression using physio-
logical and radiological criteria and, in addition, from
changes in disease stage using the updated GOLD classifi-
cation [16]. The study was approved by the local ethics
committee and patients provided written informed con-
sent.
Sputum analysis
Spontaneously produced sputum samples were obtained
at baseline in the stable clinical state, at least two months
after any exacerbation. Samples were collected over four
hours after waking and quantitative bacterial culture was
performed on an aliquot [17]. The remaining material
was centrifuged to obtain the sol-phase for the assay of
myeloperoxidase (MPO), interleukin-8 (IL-8), leukot-
riene B4 (LTB4) and albumin as described previously
[18]. Myeloperoxidase activity in sol-phase sputum was
measured by chromogenic substrate assay relative to a
known standard (Sigma Aldrich, Poole, Dorset, UK). IL-8
and LTB4 in sol-phase sputum were measured by ELISA
using commercially available kits (Quantikine, R&D Sys-
tems Europe Ltd, Abingdon, UK and Amersham Interna-
tional plc, Buckinghamshire, UK, respectively). Sol-phase
albumin was measured by radial immunodiffusion using
a commercially available kit (The Binding Site Limited,
Birmingham, UK). Ten ml of clotted venous blood was
used to determine the serum albumin concentration using
the same method given for sputum analysis, and the spu-
tum/serum albumin ratio was calculated in order to assess
airspace protein leakage.
Lung function testing
Lung function testing was performed at baseline and 4
years later. Spirometry was performed using a wedge-bel-
lows (Vitalograph Ltd, Buckinghamshire, UK) both before
and following inhalation of 400 mcg of salbutamol and
60 mcg of ipratropium bromide via a large volume spacer
device. Lung volumes were measured by helium dilution
(Morgan Medical, Kent, UK), and diffusing capacity for
carbon monoxide (Tlco) and transfer coefficient (KCO)
was determined using the single breath method [19].
Baseline and follow-up measurements were performed on
the same equipment according to national quality control
guidelines [20], and results were expressed as a percentageRespiratory Research 2006, 7:136 http://respiratory-research.com/content/7/1/136
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of predicted values. Post-bronchodilation values were
used for the assessment of decline in lung function.
Computed tomography and lung densitometry
Whole lung computed tomography scans were performed
at full inspiration, on a General Electric Prospeed scanner
at baseline and four years later, using a high-resolution
protocol (120kVp, 200mAs, 1 mm collimation at 10 mm
intervals, 'bone' reconstruction algorithm). All scans were
visually assessed for the presence of emphysema and
bronchiectasis by a radiologist (P.J.G.) using established
criteria [21,22].
Lung densitometry was performed on selected images at
the level of the aortic arch ('Upper Zones') and the inferior
pulmonary veins ('Lower Zones') using semi-automated
computer software (Pulmo-CMS, MEDIS Medical Imag-
ing Systems BV, Leiden, the Netherlands) as described pre-
viously [23]. Two densitometric indices were measured;
the voxel index -950 (V.I.-950), which is defined as the
proportion of lung voxels below a threshold of -950
Hounsfield Units (HU) and the 15th  percentile point
(Perc15), which is the cut off value in HU below which
15% of voxels are distributed. These methods have been
validated against pathology [10,11] and used in previous
clinical studies [12,23,24].
A standardised rate of change was calculated for each
parameter by dividing the difference between the two val-
ues by the time elapsed between the tests in order to over-
come minor variability in the duration of follow-up.
Statistical analysis
Statistical analyses were performed using the SPSS statisti-
cal programme (version 11.5 Chicago, Il). Data were
tested for normality using the Shapiro-Wilk test. Normally
distributed data are reported as the mean and standard
deviation (SD) and comparisons made with the t-test.
Non-parametric data are reported as the median and
interquartile range [IQR]) and comparisons were made
with the Wilcoxon signed rank test for paired data and the
Mann Whitney-U test for grouped data. Relationships
between variables were examined using Spearman's rank
correlation test and categorical data were compared with
the Chi-squared test. A p value of less than 0.05 was con-
sidered to be statistically significant.
Results
Baseline subject characteristics
Sixty-five patients agreed to participate in the follow-up
study but complete physiological and imaging data could
only be obtained in 56 patients. All subjects had a history
of chronic bronchitis [14] and no patients had alpha 1-
antitrypsin deficiency. The mean (standard deviation –
s.d.) age at baseline was 63 (7.4), and 29 (52%) of
patients were male. More than half (30) of patients were
current smokers and the mean (s.d.) number of pack years
was 55 (39.9). The individual data for FEV1 (% predicted)
and TLCO (% predicted) are indicated in Figure 1. The
mean (s.d.) FEV1 was 1.89 L (0.71 L) (76.8 % predicted)
and the mean (s.d.) FEV1/FVC was 56.6 (17.2). The base-
line characteristics of the 38 patients with inflammatory
data were comparable to the whole group (data not
shown). The number of patients assigned to each GOLD
category is indicated in Figure 2 and the baseline physiol-
ogy for each category is shown in Table 1.
Spontaneous sputum was obtained from 47 patients at
baseline. Microbiological assessment was performed on
all samples but sufficient sputum sol-phase for inflamma-
tory analysis was available from only 38 subjects. The
baseline concentrations of markers of sputum inflamma-
tion are as follows, expressed as median (interquartile
range), [number of patients]: myeloperoxidase, 0.33
units/ml (0.20–0.86) [n = 37]; leukotriene B4, 4.39nM
(1.71–6.98) [n = 36]; interleukin 8, 1.75 (0.78–7.78) [n =
38]; albumin leakage, 0.58% (0.28–1.17) [n = 35]. Spu-
tum colonization with recognised respiratory pathogens
was seen in 18 of the 38 subjects but complete data on
exacerbations throughout the study period was not avail-
able. CT evidence of mild, limited, tubular bronchiectasis
was visualised in seven of the 38 subjects. Visual evidence
of emphysema was present in 34 subjects and this
included 6 of the 19 subjects who were classed as 'at risk'
by the GOLD staging system.
Disease progression
The mean interval between baseline and follow-up assess-
ment for the whole group was 3.99 years (s.d.- 0.7). Thirty
patients were smoking at baseline but 15 quit their smok-
ing habit during the course of the study. In addition, some
treatment changes were recorded over the 4 year period:
inhaled corticosteroid therapy had been commenced in 8
patients and the number of patients treated with inhaled
long-acting beta agonists had increased from 6 at baseline
to 19.
Statistically significant disease progression over the course
of the study was demonstrated by a decline in FEV1, FVC
and gas transfer (Table 2), and reduced lung density
(Table 3). Disease progression was also evident in the
reassignment of patients to more advanced disease stages
as defined in the GOLD classification (Figure 2). Out of
the 19 patients originally classified as stage 0 at baseline,
6 had evidence of emphysema and, of these, 3 required
reclassification into the 'mild' category and 2 required
reclassification into the 'moderate' category at follow-up.
The decline of FEV1 in the 19 subjects who were classified
at baseline as stage 0, was 46.5 ml (95% confidence inter-
val, 25.0 to 68.1 ml), compared to 31.5 ml (95% confi-Respiratory Research 2006, 7:136 http://respiratory-research.com/content/7/1/136
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dence interval, 11.8 to 51.3 ml) in the remaining subjects
in GOLD stages 1 to 4. Fourteen subjects remained in the
'at risk' group after 4 years, 3 had progressed to GOLD
stage 1, and 2 subjects had progressed to GOLD stage 2.
No significant change was demonstrated in total lung
capacity (TLC), residual volume (RV) or RV/TLC (Table
2).
The changes in physiological and CT indices observed in
the 38 subjects with data on baseline inflammation were
comparable to those seen in the whole group (data not
shown).
Relationship between baseline characteristics and disease 
progression
The loss of lung density measured from CT imaging was
greater in women than men, particularly in the upper
zones (Table 4). The rate of progression of CT indices in
the upper zones was greater in continuing smokers than in
ex-smokers (median increase in upper zone VI = 0.62%
[IQR 0.14–1.57] v 0.17% [IQR -0.24–0.51] respectively, p
= 0.002).
Sputum bacterial colonization at baseline did not relate to
the subsequent rate of physiological and radiological pro-
gression. In addition, there was no demonstrable relation-
ship between FEV1 at baseline, smoking status at baseline,
sex, age, drug therapy (including inhaled corticosteroid)
and the presence of visible emphysema or bronchiectasis
on CT, and the subsequent rate of decline in FEV1.
In the sub-group of patients with data on sputum inflam-
mation, baseline levels of sputum myeloperoxidase corre-
lated with the subsequent decline in FEV1 (rs = -0.344, p =
0.019, n = 37) (Figure 3) and FVC (rs = -0.334, p = 0.022,
n = 37). This relationship was consistent for the decline in
FVC (rs = -0.387, p = 0.017) following exclusion of the 7
patients with mild tubular bronchiectasis, but there was
only a trend towards significance for FEV1 (rs = -0.254, p
= 0.096).
Individual data for the FEV1 and TLCO measurements at baseline, expressed as percent predicted, (n = 56) Figure 1
Individual data for the FEV1 and TLCO measurements at baseline, expressed as percent predicted, (n = 56).
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The concentration of LTB4 at baseline correlated with the
annual decline in FVC (rs = -0.441, p = 0.004, n = 36) (Fig-
ure 4) and this relationship persisted following exclusion
of the 7 subjects with bronchiectasis (rs = -0.440, p =
0.008).). The LTB4 concentration was also related to the
decline in TLCO (rs = -0.310; p = 0.033, n = 35) but did
not correlate with the decline in FEV1. Albumin leak was
related to decline in FVC (rs = -0.321, p = 0.03, n = 35) and
TLCO (rs = -0.401; p = 0.008, n = 35). When subjects with
bronchiectasis were excluded, a statistically significant
relationship with TLCO could be demonstrated for LTB4
(rs = -0.432, p = 0.032, n = 29) but there was only a trend
towards significance for albumin leak (rs = -0.241, p =
0.096, n = 29). Sputum IL-8 did not relate to FEV1 decline
and the decline in KCO did not relate to any marker of
progression.
The level of IL-8 in baseline sputum correlated with the
changes in CT densitometry (Table 5). These relationships
remained statistically significant following the exclusion
of subjects with bronchiectasis (Figure 5) and also follow-
ing the exclusion of subjects who were colonised with
pathogenic bacteria (data not shown).
Conclusion
The current study provides unique data on the progres-
sion of physiological and radiological indices of disease
severity over a four-year interval in a cohort of subjects
with COPD and chronic bronchitis. In addition, it has
demonstrated that markers of inflammation measured
from a single sputum sample obtained at baseline are
related to subsequent disease progression.
Subject selection was restricted to individuals with a clin-
ical phenotype of chronic bronchitis but evidence of dis-
ease progression was demonstrated by changes in both
physiology (Tables 2) and CT densitometry (Tables 3, 4
and 5). Progressive airflow obstruction was demonstrated
over a 4 year interval with a measured rate of decline in
FEV1 that is consistent with previous findings [25,26]. A
Distribution of patients according to GOLD staging category at baseline (open histograms) and at follow-up, four years later  (grey histograms) Figure 2
Distribution of patients according to GOLD staging category at baseline (open histograms) and at follow-up, 
four years later (grey histograms). There was a significant redistribution in the disease stage towards more severe disease 
over the study period. The significance (p) is shown for the Wilcoxon signed rank test. The figures in brackets indicate the 
number of subjects within each group that contributed to data relating to sputum inflammation.Respiratory Research 2006, 7:136 http://respiratory-research.com/content/7/1/136
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decline in gas transfer (Table 2) and reduction in CT den-
sitometry (Table 3) indicate that a proportion of this
decline was likely secondary to progression of emphy-
sema.
Disease progression was also evident in the re-assignment
of subjects into more severe GOLD sub-groups after an
interval of just four years. The progression of some indi-
viduals from GOLD stage 0 ('at risk') into the 'mild' and
'moderate' categories is pertinent because the inclusion of
the stage 0 grouping in the revised GOLD guidelines has
been controversial [27]. Furthermore, it is noteworthy
that, despite the absence of physiological impairment,
emphysema was visible on the baseline scans in 6 of the
19 'at risk' subjects. These findings justify the inclusion of
stage 0 in the severity staging of COPD but suggest that
use of the term 'at risk' may be falsely reassuring. Future
studies are needed to further characterise this group of
subjects in order to identify individuals who are at higher
risk, and to enable early intervention.
The data relating sputum inflammation to subsequent
disease progression in a sub-group of individuals
uniquely provides direct evidence of causation. Previous
studies have related airway and sputum inflammation to
disease severity [3-6,28], but such data cannot distinguish
cause from effect. The current study has demonstrated that
higher levels of various sputum inflammatory markers are
associated with a greater rate of subsequent decline in
lung function and, in addition, that the level of sputum
IL-8 is associated with subsequent progression of emphy-
sema.
The latter relationship is of particular interest because spu-
tum IL-8 is a reflection of inflammation within the proxi-
mal rather than the distal airways where emphysematous
destruction occurs. Nevertheless, the association between
IL-8 levels in BAL fluid and the presence of early sub-clin-
ical emphysema [29] supports the role of IL-8 in the devel-
opment of emphysema and the findings of the current
study therefore suggest that inflammation in the proximal
airways may be representative of pathological changes in
the alveolar region. Furthermore, they imply the occur-
rence of a more widespread epithelial response that is
consistent with the demonstration of greater IL-8 expres-
Table 1: Baseline characteristics of patients according to GOLD category
Stage 0 n = 19 Stage 1 n = 9 Stage 2 n = 21 Stage 3 n = 4 Stage 4 n = 3
FEV1 (L) 2.54 (0.49) 2.06 (0.41) 1.57 (0.43) 0.96 (0.17) 0.73 (0.13)
FEV1 (%pred) 101.6 (10.1) 89.1 (11.2) 63.2 (10.3) 40.2 (7.4) 27.5 (2.3)
FVC (L) 3.39 (0.69) 3.61 (0.70) 3.38 (1.12) 3.17 (1.07) 2.83 (0.49)
FVC (%pred) 108.8 (9.6) 127.1 (22.2) 102.3 (20.4) 104.5 (14.0) 81.9 (16.4)
FEV1/FVC (%) 75.4 (6.0) 57.2 (4.5) 48.3 (10.0) 32.6 (9.5) 26.7 (7.6)
RV (L) 1.93 (0.41) 2.69 (0.56) 3.40 (0.92) 3.46 (1.02) 4.63 (1.06)
RV (%pred) 92.3 (12.7) 130.3 (24.6) 156.2 (36.5) 171.5 (34.2) 194.0 (40.5)
TLC (L) 5.44 (1.04) 6.25 (0.99) 6.59 (0.99) 6.41 (2.05) 7.01 (1.38)
TLC (%pred) 98.9 (7.9) 118.4 (12.9) 117.0 (19.3) 119.5 (17.6) 113.7 (20.5)
TLCO (mmol/min/kPa) 8.03 (2.10) 7.00 (2.28) 5.71 (2.09) 2.92 (1.18) 5.06 (1.43)
TLCO (%pred) 100.5 (21.2) 91.2 (24.3) 72.0 (21.3) 37.8 (14.8) 62.0 (13.9)
KCO (mmol/min/kPa/L) 1.60 (0.32) 1.33 (0.38) 1.14 (0.41) 0.69 (0.33) 1.14 (0.36)
KCO (%pred) 110.3 (23.4) 93.4 (31.6) 81.4 (29.2) 46.0 (20.9) 86.7 (27.5)
Figures represent the mean (standard deviation).
Table 2: Change in physiological measurements over the study period (n = 56)
Baseline (sd) Follow up (sd) Annual change (95% confidence interval) p value
FEV1 (L) 1.89 (0.71) 1.74 (0.68) -37.7 ml (-52.0 to -23.4), p < 0.001
FEV1 (% predicted) 76.8 (25.1) 74.0 (27.3) -0.8 (-1.5 to 0.0), p < 0.05
FVC (L) 3.38 (0.88) 3.26 (0.85) -28.9 ml (-50.4 to -7.3), p < 0.01
FVC (% predicted) 109.0 (19.3) 111.0 (25.1) 0.36 (-0.5 to 1.2), Not significant
FEV1/FVC (%) 56.6 (0.17) 53.6 (0.17) 0.75 (0.40 to 1.1), p < 0.001
TLCO (mmol/min/kpa) 6.5 (2.4) 5.8 (2.4) -0.15 (-0.21 to -0.09), p < 0.001
TLCO (% predicted) 81.8 (27.4) 76.2 (27.3) -1.3 (-2.1 to -0.6), p < 0.001
KCO (mmol/min/kpa/L) 1.3 (0.4) 1.2 (0.4) -0.02 (-0.03 to -0.01), p < 0.001
KCO (% predicted) 90.9 (31.6) 85.0 (31.4) -1.4 (-2.1 to -0.7), p < 0.001
No change in static lung volume measurements was observed over the study period.
sd = standard deviation.Respiratory Research 2006, 7:136 http://respiratory-research.com/content/7/1/136
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sion in the alveolar epithelial cells of smokers than of
non-smokers [30].
These findings are of importance in the consolidation of
current understanding of the pathogenesis of COPD and
suggest a potential method for identifying individuals at
greater risk of disease progression. Nevertheless, it is rec-
ognised that there are some limitations to the data. It was
not possible, using single measurements, to consistently
demonstrate the presence of a relationship between
inflammation and indicators of disease progression for all
measures. However, single data points may not correlate
merely because of intra-patient variability, and the use of
repeated measures would likely have improved the con-
sistency of the associations between inflammation and
markers of disease progression.
It is also recognised that the exclusion of subjects with
bronchiectasis reduced the number of identifiable associ-
ations between inflammation and disease progression.
The decision that assessment should be performed using
data for the whole group and also following the exclusion
of subjects with radiological evidence of bronchiectasis
was made a priori because of the recognised influence of
bronchiectasis on bronchial inflammation [31]. Notwith-
standing the reduction that this exclusion had on the size
of the study population, and the likelihood of identifying
a statistically significant relationship, such a relationship
was nevertheless maintained for some parameters. Conse-
quently, it cannot be concluded that the relationship
between sputum inflammation and disease progression is
merely a reflection of the presence of bronchiectasis. Fur-
thermore, it is important to recognise, given the clinical
phenotype of 'chronic bronchitis', that the presence of
mild tubular bronchiectasis on CT was likely a co-inciden-
tal finding of uncertain clinical significance.
There are a number of other confounding variables that
merit discussion. Smoking status changed in 15 subjects
and it is probable that subsequent inflammation and dis-
ease progression would have been influenced by these
changes. Nevertheless, it is unsurprising that we were not
able to demonstrate the influence of changes in smoking
status on disease progression in such a small sample size.
The adjustment of COPD-related therapy in accordance
with normal clinical practice was reported in 24 individu-
als (8 patients were commenced on inhaled corticoster-
oids and the number of patients prescribed long-acting
Table 3: Changes in CT lung density (n = 56)
Scan 1 Scan 2 Median change/yr Z statistic
Upper zone -916.45 -926.7 -1.11 -3.59 (p ≤ 0.001)
Perc15 (HU) (-952.3 to -902.2) (-960.1 to -912.9) (-4.05 to -0.12)
Upper zone 4.58 7.20 0.29 -4.05 (p ≤ 0.001)
VI -950HU (%) (2.31 to 15.98) (3.74 to 19.32) (0.02 to 0.90)
Lower zone -919.23 -923.24 -0.82 -2.20 (p < 0.05)
Perc15 (HU) (-947.0 to -895.6) (-948.4 to -906.1) (-3.05 to 1.37)
Lower zone 4.79 6.46 0.20 -3.43 (p ≤ 0.001)
VI -950HU (%) (1.89 to 11.35) (3.25 to 14.62) (-0.12 to 0.73)
The data was not normally distributed and therefore is presented as median with interquartile range in parentheses. The Z-statistic derived from 
the Wilcoxon signed rank test is shown for the change in all CT parameters with p values in parentheses. VI = voxel index, Perc15 = 15th percentile 
point, HU = Hounsfield Units.
Table 4: Sex differences in CT density changes (n = 56)
Men (n = 29) Women (n = 27) p value
Upper Zone -0.6 -2.2 p = 0.006
Perc15 (HU) (-2.11 to 0.8) (-5.2 to -0.7)
Upper Zone 0.17 0.46 p < 0.03
VI -950HU (%) (-0.27 to 0.70) (0.15 to 1.08)
Lower Zone 0.23 -1.89 p < 0.05
Perc15 (HU) (-1.68 to 1.71) (-5.67 to 0.03)
Lower Zone 0.12 0.24 not significant
VI -950HU (%) (-0.17 to 0.57) (0.04 to 0.79)
The data was not normally distributed and therefore is presented as median with interquartile range in parentheses. All values are presented as a 
standardized annual rate of change.
VI = voxel index, Perc15 = 15th percentile point, HU = Hounsfield UnitsRespiratory Research 2006, 7:136 http://respiratory-research.com/content/7/1/136
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Individual data indicating the relationship between baseline sputum myeloperoxidase activity and annual change in FEV1 Figure 3
Individual data indicating the relationship between baseline sputum myeloperoxidase activity and annual 
change in FEV1. Spearman's correlation coefficient (r) and its significance (p) are indicated.
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Individual data indicating the relationship between baseline sputum LTB4 concentration and annual change in FVC Figure 4
Individual data indicating the relationship between baseline sputum LTB4 concentration and annual change in 
FVC. Spearman's correlation coefficient (r) and its significance (p) are indicated.
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beta agonists increased from 6 at baseline to 19 at follow-
up). We did not explore the potential influence of these
therapeutic changes on the progression of disease because
it is generally understood that current pharmaceutical
treatment does not modify the natural history of COPD
and the current study was not powered for such analyses.
The inflammatory response that is the pathological hall-
mark of COPD is a complex process involving several dif-
ferent mechanisms, although the relative importance of
these pathological processes remains undetermined. The
current study of subjects with COPD and chronic bronchi-
tis demonstrates that prospective measurements of mark-
Individual data (excluding subjects with mild bronchiectasis) indicating the relationship between baseline sputum IL-8 concen- tration and emphysema progression in the upper lung region (voxel index at a threshold -950HU) Figure 5
Individual data (excluding subjects with mild bronchiectasis) indicating the relationship between baseline spu-
tum IL-8 concentration and emphysema progression in the upper lung region (voxel index at a threshold -
950HU). Spearman's correlation coefficient (r) and its significance (p) are indicated.
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Table 5: Correlation (Spearman's rho) between CT densitometry and baseline IL-8
All patients (n = 38) Excluding tubular bronchiectasis (n = 31)
UZ Perc15 rs = -0.464 (p = 0.005) rs = -0.558 (p ≤ 0.001)
UZ VI -950HU rs = 0.447 (p = 0.005) rs = 0.591 (p ≤ 0.001)
LZ Perc15 rs = -0.447 (p = 0.005) rs = -0.454 (p = 0.005)
LZ VI -950HU rs = 0.353 (p ≤ 0.02) rs = 0.401 (p ≤ 0.02)
UZ = upper zone, LZ = lower zone, VI = voxel index, Perc15 = 15th percentile point, HU = Hounsfield Units.Respiratory Research 2006, 7:136 http://respiratory-research.com/content/7/1/136
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ers that relate to neutrophilic inflammation in sputum are
associated with the rate of subsequent disease progres-
sion. Consequently, the data are of critical importance in
establishing the role of this inflammatory mechanism in
the pathogenesis of COPD. In addition, they indicate that
markers of lung inflammation in COPD are of potential
value for risk stratification in clinical practice and, further-
more, may assist in guiding contemporary strategies for
the development of effective disease modifying therapy.
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